TempraMed Technologies Ltd.

TempraMed Technologies Ltd.

0.18
EUR
-0.05
(-22.69%)
-0.24EPS
30.10MMarket Cap

Total Valuation

EUR

As of June 30, 2026, TempraMed Technologies Ltd. carries a market capitalization of 30.10M, placing it among publicly traded companies globally. Its enterprise value stands at 31.47M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap30.10M
Enterprise Value31.47M

Share Statistics

As of June 30, 2026, TempraMed Technologies Ltd. has 79.01M shares outstanding.

Shares Outstanding79.01M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 16.89, and the price-to-book ratio stands at -11.69.

PS Ratio16.89
PB Ratio-11.69
P/TBV Ratio-11.69
P/FCF Ratio-7.14
P/OCF Ratio-7.14

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 18.47 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 31.47M versus a market cap of 30.10M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales18.47

Financial Position

As of June 30, 2026, TempraMed Technologies Ltd. maintains a current ratio of 0.25, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -54.03, indicating conservative leverage, while an interest coverage ratio of -24.76 demonstrates limited ability to service its debt obligations.

Current Ratio0.25
Quick Ratio0.10
Debt / Equity-54.03
Debt / EBITDA-0.23
Interest Coverage-24.76

Financial Efficiency

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -892.55, reflecting losses generated across the asset base. Inventory turnover of 2.82 indicates how many times TempraMed Technologies Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-892.55
Inventory Turnover2.82

Stock Price Statistics

EUR

These figures are as of the close on November 17, 2026. The 50-day moving average sits at 0.25, while the 200-day moving average is 0.37.

50-Day Moving Average0.25
200-Day Moving Average0.37

Income Statement

EUR

Over the twelve months ended June 30, 2026, TempraMed Technologies Ltd. generated 1.70M in revenue and converted that into -17.86M in net income, yielding earnings per share of -0.24. EBITDA reached -6.09M, while operating income came in at -6.14M.

Revenue1.70M
Gross Profit747,506.20
Operating Income-6.14M
Pretax Income-17.86M
Net Income-17.86M
EBITDA-6.09M
EBIT-6.14M
Earnings Per Share (EPS)-0.24

Balance Sheet

EUR

As of June 30, 2026, TempraMed Technologies Ltd. holds 24,508.40 in cash and equivalents against 1.39M in total debt, resulting in a net debt position of 1.37M. Total book value stands at -2.58M, with working capital of -2.13M providing operational flexibility.

Cash & Cash Equivalents24,508.40
Total Debt1.39M
Net Debt1.37M
Equity (Book Value)-2.58M
Book Value Per Share-0.03
Working Capital-2.13M

Cash Flow

EUR

TempraMed Technologies Ltd. produced -4.03M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -875.30 in capital expenditures, free cash flow totaled -4.03M - equivalent to -0.05 per share.

Operating Cash Flow-4.03M
Capital Expenditures-875.30
Free Cash Flow-4.03M
FCF Per Share-0.05

Margins

Over the twelve months ended June 30, 2026, TempraMed Technologies Ltd. posted a gross margin of 43.86, reflecting its pricing power and cost economics. The operating margin of -360.30 and net profit margin of -1,047.87 provide insight into operational efficiency.

Gross Margin43.86
Operating Margin-360.30
Pretax Margin-1,047.87
Profit Margin-1,047.87
EBITDA Margin-357.37

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -14.00: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -13.73, meaning TempraMed Technologies Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-13.73
FCF Yield-14.00

Scores

As of June 30, 2026, TempraMed Technologies Ltd. has an Altman Z-Score of -57.45, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-57.45